SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve
Speaker: O. Wendler
Explore the SOURCE 3 Registry: Real-World Evidence With the Edwards SAPIEN 3 Transcatheter Heart Valve
At EuroPCR 2017, new one-year data from a post-approval study of the Edwards SAPIEN 3 valve demonstrated positive patient outcomes, including high survival rates, low rates of stroke, and low rates of paravalvular leak.
The majority of patients in the SOURCE 3 Registry were treated via transfemoral access, and more than half were treated under conscious sedation. SOURCE 3 patients were enrolled at 80 centres across 10 countries between July 2014 and October 2015, and will continue to be followed for five years post-TAVI.
Growing clinical evidence with the ACURATE neo™ TAVI System
Summary: Join S. Redwood, S. Toggweiler and H. Moellmann as theyDiscuss the advantages of the ACURATE neo™ intuitive and predictable implantation procedure with a unique “top-down” deployment Highlight the latest clinical data from the 1-Year follow-up of the SAVI-TF 1000 global registry1
LOTUS™ Valve PPM Rate: New data shows a downward trend in Permanent Pacemaker Rate (PPM)
The LOTUS™ Valve System is a controlled mechanical expansion TAVI technology, designed to provide unmatched freedom from PVL, precise delivery and deployment, and predictable results.
Case Study: Complex Left Main with Two Sidebranches
Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy
Watchman™ Ewolution prospective registry - 3 months results & clinical impact
Case Study: A Tale of 4 Bifurcations
12 Jan 2017
Interventional Cardiologists are being presented with more complex patients, understanding stent platform characteristics and DAPT requirements is becoming increasingly important. Find out more about this case presented by C. Owens.
In this section, you will find content donated by our Industry Partners working in the field of Interventional Cardiovascular Disease. This content is considered to be of educational value and is not intended as advertising. Publication on this website does not equal endorsement. Discover the promoted content ...
In this section you will find industry partners' viewpoints on device development and perspectives for the coming year.